Scinai Immunotherapeutics (SCNI) Share-based Compensation (2018 - 2026)
Scinai Immunotherapeutics' (SCNI) quarterly Share-based Compensation came in at $232000.0 in Q2 2026, up 7633.33% year-over-year from $3000.0 in Q2 2025, and up 231.43% quarter-over-quarter from $70000.0 in Q1 2026.
Powered by 
Analysis
Scinai Immunotherapeutics (SCNI) Share-based Compensation (2018 - 2026) Analysis & Trends
Scinai Immunotherapeutics has disclosed Share-based Compensation across 9 years of filings, most recently posting $232000.0 for Q2 2026.
- In Q2 2026, Share-based Compensation rose 7633.33% year-over-year to $232000.0; the TTM figure through Jun 2026 stood at $232000.0 (up 7633.33% YoY), while the FY2025 annual figure was $510.4 million, up 424.98% from the prior year.
- Share-based Compensation came in at $232000.0 for Q2 2026 at Scinai Immunotherapeutics, up from $70000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $650000.0 in Q2 2024 to a low of $3000.0 in Q2 2025.
- Average Share-based Compensation over 5 years is $284875.0, with a median of $243000.0 recorded in 2023.
- Year-over-year, Share-based Compensation slumped 99.54% in 2025 and soared 7633.33% in 2026.
- Over 5 years, Share-based Compensation stood at $398000.0 in 2022, then grew by 13.82% to $453000.0 in 2023, then plunged by 54.97% to $204000.0 in 2024, then surged by 54.41% to $315000.0 in 2025, then retreated by 26.35% to $232000.0 in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $232000.0 in Q2 2026, $70000.0 in Q1 2026, and $315000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Scinai Immunotherapeutics | 1.52 Bn | 1.52 Bn | -1.25 Mn | 232,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 232,000.00 |
| Mar 31, 2026 | 70,000.00 |
| Dec 31, 2025 | 315,000.00 |
| Jun 30, 2025 | 3,000.00 |
| Dec 31, 2024 | 204,000.00 |
| Sep 30, 2024 | 145,000.00 |
| Jun 30, 2024 | 650,000.00 |
| Mar 31, 2024 | 191,000.00 |
| Dec 31, 2023 | 453,000.00 |
| Sep 30, 2023 | 234,000.00 |
| Jun 30, 2023 | 207,000.00 |
| Mar 31, 2023 | 252,000.00 |
| Dec 31, 2022 | 398,000.00 |
| Sep 30, 2022 | 313,000.00 |
| Jun 30, 2022 | 406,000.00 |
| Mar 31, 2022 | 485,000.00 |
| Dec 31, 2021 | 727,000.00 |
| Sep 30, 2021 | 2.53 Mn |
| Jun 30, 2021 | 2.58 Mn |
| Mar 31, 2021 | 437,000.00 |